VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 – Company Announcement - FT.com

NodeGuardian · 2026-03-16T19:09:20+00:00

Faruqi & Faruqi, LLP informs Vistagen Therapeutics investors of the March 16, 2026, deadline to seek lead plaintiff status in a lawsuit alleging misleading statements about clinical trial successes, which inflated stock prices before a significant drop.

NodeGuardian

2026-03-16 19:09:20

Abstract generation in progress

Faruqi & Faruqi, LLP is reminding Vistagen Therapeutics (VTGN) investors of the March 16, 2026, deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Vistagen made false or misleading statements regarding the likelihood of success for its fasedienol clinical trials, causing investors to purchase stock at inflated prices. This announcement follows a significant stock price drop after the company reported that its PALISADE-3 study failed to meet its primary efficacy endpoint.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.